PAF-induced airway responses in sheep: Effects of a PAF antagonist and nedocromil sodium

M. Soler, E. Mansour, A. Fernandez, J. D'Brot, T. Ahmed, W. M. Abraham

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Platelet-activating factor (PAF) is a potent inflammatory mediator that can cause bronchoconstriction and airway hyperresponsiveness in selected human subjects and animals. The mechanism by which PAF induces these changes is not clearly understood. We therefore studied the effects of intratracheal instillation of PAF (30 μg/kg) on airway resistance and airway responsiveness in allergic sheep (n = 7) and attempted to modulate these effects with the specific PAF antagonist, WEB-2086, and the antiasthmatic agent, nedocromil sodium (NED). Specific lung resistance (SRL) was measured to assess bronchial responses to PAF, and airway responsiveness was determined by deriving a provocative dose of carbachol in breath units causing an increase in SRL to 4 L times centimeters of H2O per liters per second (PD4) from carbachol dose-response curves. PAF instillation increased mean ± SD SRL to 228 ± 134% above baseline. Two to 4 hours after PAF instillation, PD4 decreased by 55 ± 9% from a baseline of 39 ± 9 breath units (p < 0.05). Airway responsiveness remained increased at 24 hours but returned to baseline by 48 hours. Pretreatment with WEB-2086 (3 mg/kg, intravenously) or NED (1 mg/kg, nebulized) blocked (p < 0.05,) PAF-induced bronchoconstriction and PAF-induced airway hyperresponsiveness. Instillation of lyso-PAF (30 μg/kg) did not cause bronchoconstriction or airway hyperresponsiveness. Thus, instilled PAF causes bronchoconstriction and airway hyperresponsiveness in allergic sheep by a receptor-mediated mechanism that likely involves the release of secondary mediators, the latter process being sensitive to NED.

Original languageEnglish
Pages (from-to)661-668
Number of pages8
JournalJournal of Allergy and Clinical Immunology
Volume85
Issue number3
StatePublished - Dec 1 1990
Externally publishedYes

Fingerprint

Nedocromil
Platelet Activating Factor
Sheep
Bronchoconstriction
WEB 2086
Carbachol
Anti-Asthmatic Agents
Airway Resistance

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Soler, M., Mansour, E., Fernandez, A., D'Brot, J., Ahmed, T., & Abraham, W. M. (1990). PAF-induced airway responses in sheep: Effects of a PAF antagonist and nedocromil sodium. Journal of Allergy and Clinical Immunology, 85(3), 661-668.

PAF-induced airway responses in sheep : Effects of a PAF antagonist and nedocromil sodium. / Soler, M.; Mansour, E.; Fernandez, A.; D'Brot, J.; Ahmed, T.; Abraham, W. M.

In: Journal of Allergy and Clinical Immunology, Vol. 85, No. 3, 01.12.1990, p. 661-668.

Research output: Contribution to journalArticle

Soler, M, Mansour, E, Fernandez, A, D'Brot, J, Ahmed, T & Abraham, WM 1990, 'PAF-induced airway responses in sheep: Effects of a PAF antagonist and nedocromil sodium', Journal of Allergy and Clinical Immunology, vol. 85, no. 3, pp. 661-668.
Soler M, Mansour E, Fernandez A, D'Brot J, Ahmed T, Abraham WM. PAF-induced airway responses in sheep: Effects of a PAF antagonist and nedocromil sodium. Journal of Allergy and Clinical Immunology. 1990 Dec 1;85(3):661-668.
Soler, M. ; Mansour, E. ; Fernandez, A. ; D'Brot, J. ; Ahmed, T. ; Abraham, W. M. / PAF-induced airway responses in sheep : Effects of a PAF antagonist and nedocromil sodium. In: Journal of Allergy and Clinical Immunology. 1990 ; Vol. 85, No. 3. pp. 661-668.
@article{8101122674f9442696cee97fb665a2e8,
title = "PAF-induced airway responses in sheep: Effects of a PAF antagonist and nedocromil sodium",
abstract = "Platelet-activating factor (PAF) is a potent inflammatory mediator that can cause bronchoconstriction and airway hyperresponsiveness in selected human subjects and animals. The mechanism by which PAF induces these changes is not clearly understood. We therefore studied the effects of intratracheal instillation of PAF (30 μg/kg) on airway resistance and airway responsiveness in allergic sheep (n = 7) and attempted to modulate these effects with the specific PAF antagonist, WEB-2086, and the antiasthmatic agent, nedocromil sodium (NED). Specific lung resistance (SRL) was measured to assess bronchial responses to PAF, and airway responsiveness was determined by deriving a provocative dose of carbachol in breath units causing an increase in SRL to 4 L times centimeters of H2O per liters per second (PD4) from carbachol dose-response curves. PAF instillation increased mean ± SD SRL to 228 ± 134{\%} above baseline. Two to 4 hours after PAF instillation, PD4 decreased by 55 ± 9{\%} from a baseline of 39 ± 9 breath units (p < 0.05). Airway responsiveness remained increased at 24 hours but returned to baseline by 48 hours. Pretreatment with WEB-2086 (3 mg/kg, intravenously) or NED (1 mg/kg, nebulized) blocked (p < 0.05,) PAF-induced bronchoconstriction and PAF-induced airway hyperresponsiveness. Instillation of lyso-PAF (30 μg/kg) did not cause bronchoconstriction or airway hyperresponsiveness. Thus, instilled PAF causes bronchoconstriction and airway hyperresponsiveness in allergic sheep by a receptor-mediated mechanism that likely involves the release of secondary mediators, the latter process being sensitive to NED.",
author = "M. Soler and E. Mansour and A. Fernandez and J. D'Brot and T. Ahmed and Abraham, {W. M.}",
year = "1990",
month = "12",
day = "1",
language = "English",
volume = "85",
pages = "661--668",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - PAF-induced airway responses in sheep

T2 - Effects of a PAF antagonist and nedocromil sodium

AU - Soler, M.

AU - Mansour, E.

AU - Fernandez, A.

AU - D'Brot, J.

AU - Ahmed, T.

AU - Abraham, W. M.

PY - 1990/12/1

Y1 - 1990/12/1

N2 - Platelet-activating factor (PAF) is a potent inflammatory mediator that can cause bronchoconstriction and airway hyperresponsiveness in selected human subjects and animals. The mechanism by which PAF induces these changes is not clearly understood. We therefore studied the effects of intratracheal instillation of PAF (30 μg/kg) on airway resistance and airway responsiveness in allergic sheep (n = 7) and attempted to modulate these effects with the specific PAF antagonist, WEB-2086, and the antiasthmatic agent, nedocromil sodium (NED). Specific lung resistance (SRL) was measured to assess bronchial responses to PAF, and airway responsiveness was determined by deriving a provocative dose of carbachol in breath units causing an increase in SRL to 4 L times centimeters of H2O per liters per second (PD4) from carbachol dose-response curves. PAF instillation increased mean ± SD SRL to 228 ± 134% above baseline. Two to 4 hours after PAF instillation, PD4 decreased by 55 ± 9% from a baseline of 39 ± 9 breath units (p < 0.05). Airway responsiveness remained increased at 24 hours but returned to baseline by 48 hours. Pretreatment with WEB-2086 (3 mg/kg, intravenously) or NED (1 mg/kg, nebulized) blocked (p < 0.05,) PAF-induced bronchoconstriction and PAF-induced airway hyperresponsiveness. Instillation of lyso-PAF (30 μg/kg) did not cause bronchoconstriction or airway hyperresponsiveness. Thus, instilled PAF causes bronchoconstriction and airway hyperresponsiveness in allergic sheep by a receptor-mediated mechanism that likely involves the release of secondary mediators, the latter process being sensitive to NED.

AB - Platelet-activating factor (PAF) is a potent inflammatory mediator that can cause bronchoconstriction and airway hyperresponsiveness in selected human subjects and animals. The mechanism by which PAF induces these changes is not clearly understood. We therefore studied the effects of intratracheal instillation of PAF (30 μg/kg) on airway resistance and airway responsiveness in allergic sheep (n = 7) and attempted to modulate these effects with the specific PAF antagonist, WEB-2086, and the antiasthmatic agent, nedocromil sodium (NED). Specific lung resistance (SRL) was measured to assess bronchial responses to PAF, and airway responsiveness was determined by deriving a provocative dose of carbachol in breath units causing an increase in SRL to 4 L times centimeters of H2O per liters per second (PD4) from carbachol dose-response curves. PAF instillation increased mean ± SD SRL to 228 ± 134% above baseline. Two to 4 hours after PAF instillation, PD4 decreased by 55 ± 9% from a baseline of 39 ± 9 breath units (p < 0.05). Airway responsiveness remained increased at 24 hours but returned to baseline by 48 hours. Pretreatment with WEB-2086 (3 mg/kg, intravenously) or NED (1 mg/kg, nebulized) blocked (p < 0.05,) PAF-induced bronchoconstriction and PAF-induced airway hyperresponsiveness. Instillation of lyso-PAF (30 μg/kg) did not cause bronchoconstriction or airway hyperresponsiveness. Thus, instilled PAF causes bronchoconstriction and airway hyperresponsiveness in allergic sheep by a receptor-mediated mechanism that likely involves the release of secondary mediators, the latter process being sensitive to NED.

UR - http://www.scopus.com/inward/record.url?scp=0025273338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025273338&partnerID=8YFLogxK

M3 - Article

C2 - 2155959

AN - SCOPUS:0025273338

VL - 85

SP - 661

EP - 668

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 3

ER -